Objectives

This study aimed to determine antibody responses in healthcare workers who receive the BNT162b2 mRNA COVID-19 vaccine and identify factors that predict the response.

Methods

We recruited healthcare workers receiving the BNT162b2 mRNA COVID-19 vaccine at the Chiba University Hospital COVID-19 Vaccine Center. Blood samples were obtained before the 1st dose and after the 2nd dose vaccination, and serum antibody titers were determined using Elecsys® Anti-SARS-CoV-2S, an electrochemiluminescence immunoassay. We established a model to identify the baseline factors predicting post-vaccine antibody titers using univariate and multivariate linear regression analyses.

Results

Two thousand fifteen individuals (median age 37-year-old, 64.3% female) were enrolled in this study, of which 10 had a history of COVID-19. Before vaccination, 21 participants (1.1%) had a detectable antibody titer (≥0.4 U/mL) with a median titer of 35.9 U/mL (interquartile range [IQR] 7.8 – 65.7). After vaccination, serum anti-SARS-CoV-2S antibodies (≥0.4 U/mL) were detected in all 1774 participants who received the 2nd dose with a median titer of 2060.0 U/mL (IQR 1250.0 – 2650.0). Immunosuppressive medication (p < 0.001), age (p < 0.001), time from 2nd dose to sample collection (p < 0.001), glucocorticoids (p = 0.020), and drinking alcohol (p = 0.037) were identified as factors predicting lower antibody titers after vaccination, whereas previous COVID-19 (p < 0.001), female (p < 0.001), time between 2 doses (p < 0.001), and medication for allergy (p = 0.024) were identified as factors predicting higher serum antibody titers.

Conclusions

Our data demonstrate that healthcare workers universally have good antibody responses to the BNT162b2 mRNA COVID-19 vaccine. The predictive factors identified in our study may help optimize the vaccination strategy.

中文翻译：

---

日本一家三级转诊医院医护人员对 BNT162b2 mRNA COVID-19 疫苗的抗体反应及其预测因素

目标

本研究旨在确定接受 BNT162b2 mRNA COVID-19 疫苗的医护人员的抗体反应，并确定预测反应的因素。

方法

我们在千叶大学医院 COVID-19 疫苗中心招募了接受 BNT162b2 mRNA COVID-19 疫苗的医护人员。在第一剂疫苗接种前和第二剂疫苗接种后采集血液样本，并使用 Elecsys® Anti-SARS-CoV-2S（一种电化学发光免疫测定法）测定血清抗体滴度。我们建立了一个模型，使用单变量和多变量线性回归分析来确定预测疫苗接种后抗体滴度的基线因素。

结果

2015 人（中位年龄 37 岁，女性占 64.3%）参加了这项研究，其中 10 人有 COVID-19 病史。在接种疫苗之前，21 名参与者 (1.1%) 具有可检测的抗体效价 (≥0.4 U/mL)，中位效价为 35.9 U/mL（四分位距 [IQR] 7.8 – 65.7）。接种疫苗后，所有 1774 名接受第二剂疫苗的参与者均检测到血清抗 SARS-CoV-2S 抗体（≥0.4 U/mL），中位滴度为 2060.0 U/mL（IQR 1250.0 – 2650.0）。免疫抑制药物 (p < 0.001)、年龄 (p < 0.001)、从第 2 次给药到样本收集的时间 (p < 0.001)、糖皮质激素 (p = 0.020) 和饮酒 (p = 0.037) 被确定为预测低抗体的因素接种疫苗后的滴度，而以前的 COVID-19 (p < 0.001)，女性 (p < 0.001)，两次剂量之间的时间 (p < 0.001)，

结论

我们的数据表明，医护人员普遍对 BNT162b2 mRNA COVID-19 疫苗具有良好的抗体反应。我们研究中确定的预测因素可能有助于优化疫苗接种策略。